Department of Health and Human Services July 2008 – Federal Register Recent Federal Regulation Documents

Results 151 - 200 of 261
Agency Information Collection Activities: Proposed Collection; Comment Request
Document Number: E8-15666
Type: Notice
Date: 2008-07-17
Agency: Agency for Healthcare Research and Quality, Department of Health and Human Services
This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request that the Office of Management and Budget (OMB) approve the proposed information collection project: ``Health Care Systems for Tracking Colorectal Cancer Screening Tests.'' In accordance with the Paperwork Reduction Act of 1995, 44 U.S.C. 3506(c)(2)(A), AHRQ invites the public to comment on this proposed information collection. This proposed information collection was previously published in the Federal Register on March 27th, 2008 and allowed 60 days for public comment. No comments were received. The purpose of this notice is to allow an additional 30 days for public comment. Changes were made to this 30 day notice to account for the electronic patient records review which were not accounted for in the 60 day notice.
National Heart, Lung, And Blood Institute; Notice of Closed Meeting
Document Number: E8-16237
Type: Notice
Date: 2008-07-16
Agency: Department of Health and Human Services, National Institutes of Health
Proposed Data Collections Submitted for Public Comment and Recommendations
Document Number: E8-16174
Type: Notice
Date: 2008-07-16
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Center for Scientific Review; Notice of Closed Meeting
Document Number: E8-15820
Type: Notice
Date: 2008-07-16
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Document Number: E8-15819
Type: Notice
Date: 2008-07-16
Agency: Department of Health and Human Services, National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Document Number: E8-16139
Type: Notice
Date: 2008-07-15
Agency: Department of Health and Human Services, National Institutes of Health
Government-Owned Inventions; Availability for Licensing
Document Number: E8-16134
Type: Notice
Date: 2008-07-15
Agency: Department of Health and Human Services, National Institutes of Health
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
National Institute for Occupational Safety and Health (NIOSH) Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board)
Document Number: E8-16065
Type: Notice
Date: 2008-07-15
Agency: Department of Health and Human Services, Centers for Disease Control and Prevention (cdc), Centers for Disease Control and Prevention
Current Good Manufacturing Practice and Investigational New Drugs Intended for Use in Clinical Trials
Document Number: E8-16011
Type: Rule
Date: 2008-07-15
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is amending the current good manufacturing practice (CGMP) regulations for human drugs, including biological products, to exempt most phase 1 investigational drugs from complying with the regulatory CGMP requirements. FDA will continue to exercise oversight of the manufacture of these drugs under FDA's general statutory CGMP authority and through review of the investigational new drug applications (IND). In addition, elsewhere in this issue of the Federal Register, FDA is announcing the availability of a guidance document entitled ``Guidance for Industry: CGMP for Phase 1 Investigational Drugs'' dated November 2007 (the companion guidance). This guidance document sets forth recommendations on approaches to compliance with statutory CGMP for the exempted phase 1 investigational drugs. FDA is taking this action to focus a manufacturer's effort on applying CGMP that is appropriate and meaningful for the manufacture of the earliest stage investigational drug products intended for use in phase 1 clinical trials while ensuring safety and quality. This action will also streamline and promote the drug development process.
Guidance for Industry: Current Good Manufacturing Practice for Phase 1 Investigational Drugs; Availability
Document Number: E8-16002
Type: Notice
Date: 2008-07-15
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of a document entitled ``Guidance for Industry: CGMP for Phase 1 Investigational Drugs'' dated July 2008. The guidance provides assistance in applying relevant current good manufacturing practice (CGMP) requirements of the Federal Food, Drug, and Cosmetic Act (the act) to the manufacture of most investigational new drugs, including biological drugs, used in phase 1 clinical trials. FDA is issuing this guidance concurrently with a final rule published elsewhere in this issue of the Federal Register specifying that compliance with FDA's CGMP regulations is not required for most investigational drugs that are manufactured for use in phase 1 clinical trials. Therefore, FDA is recommending the approaches outlined in this guidance for complying with the statutory CGMP requirements in the act. The guidance announced in this notice finalizes the draft guidance entitled ``INDsApproaches to Complying with CGMP During Phase 1'' dated January 2006.
Global Harmonization Task Force, Study Groups 1 and 3; Proposed and Final Documents; Availability
Document Number: E8-16000
Type: Notice
Date: 2008-07-15
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of final and proposed documents that have been prepared by Study Groups 1 and 3 of the Global Harmonization Task Force (GHTF), respectively. These documents represent a harmonized proposal and recommendation from the GHTF Study Groups that may be used by governments developing and updating their regulatory requirements for medical devices. These documents are intended to provide information only and do not describe FDA's current regulatory requirements; elements of these documents may not be consistent with current U.S. regulatory requirements. In particular, FDA seeks comments on the advantages and disadvantages of the approaches in the GHTF documents, particularly where they are not consistent with current practices for the manufacturer of products distributed within the United States.
Determination That SANOREX (Mazindol) Tablets 1 and 2 Milligrams Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Document Number: E8-15998
Type: Notice
Date: 2008-07-15
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing its determination that SANOREX (mazindol) Tablets, 1 and 2 milligrams (mg), were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for mazindol tablets if all other legal and regulatory requirements are met.
Advisory Committee to the Director, Centers for Disease Control and Prevention: Teleconference
Document Number: E8-15984
Type: Notice
Date: 2008-07-14
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Advisory Committee for Injury Prevention and Control (ACIPC)
Document Number: E8-15924
Type: Notice
Date: 2008-07-14
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Proposed Collection; Proposed Revision of Approved Collection; Comment Request; Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service Funding Is Sought, 42 CFR Part 50, Subpart F and for Responsible Prospective Contractors, 45 CFR Part 94
Document Number: E8-15826
Type: Notice
Date: 2008-07-14
Agency: Department of Health and Human Services, National Institutes of Health
In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Office of the Director (OD), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. Proposed Collection: Title: Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and for Responsible Prospective Contractors, 42 CFR Part 50, Subpart F, and 45 CFR Part 94. Type of Information Collection Request: Revision of OMB No. 0925- 0417, expiration date November 30, 2008. Need and Use of the Information Collection: This is a request for OMB Approval for the information collection and recordkeeping requirements contained in the final rule 42 CFR Part 50, Subpart F and related recordkeeping requirements regarding contractors in Responsible Prospective Contractors, 45 CFR Part 94. The purpose of these regulations is to promote objectivity in research by requiring institutions to establish standards to ensure that there is no reasonable expectation that the design, conduct, or reporting of research will be biased by a conflicting financial interest of an investigator. Frequency of Response: On occasion. Affected Public: Individuals or households; business or other for- profit; not-for-profit institutions; State, Local or tribal government. Type of Respondents: Any public or private entity or organization. The annual reporting burden is as follows: Estimated Number of Respondents: 67,860; Estimated Number of Responses Per Respondent: 1.60; Averaged Burden Hours per Response: 3.40.; and Estimated Total Annual Burden Hours Requested: 220,280. The annualized cost to the public is estimated at $8,120,000. Operating Costs and/or maintenance costs are $4,633.00.
National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting
Document Number: E8-15822
Type: Notice
Date: 2008-07-14
Agency: Department of Health and Human Services, National Institutes of Health
Office of Clinical and Preventive Services, Division of Nursing Services Nursing Program, Schools of Nursing
Document Number: Z8-14457
Type: Notice
Date: 2008-07-11
Agency: Department of Health and Human Services, Indian Health Service, Department of the Interior, Minerals Management Service
Request for Nominations for Voting Members on Public Advisory Committee, Food Advisory Committee
Document Number: E8-15839
Type: Notice
Date: 2008-07-11
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is requesting nominations for voting members to serve on the Food Advisory Committee (FAC), Center for Food Safety and Applied Nutrition (CFSAN). FDA has a special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on advisory committees and, therefore, encourages nominations of qualified candidates from these groups.
Draft Guidance for Industry on Providing Regulatory Submissions in Electronic Format-Drug Establishment Registration and Drug Listing; Availability
Document Number: E8-15801
Type: Notice
Date: 2008-07-11
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ``Providing Regulatory Submissions in Electronic FormatDrug Establishment Registration and Drug Listing.'' This draft guidance document establishes a Pilot Program for industry to voluntarily submit drug establishment registration and drug listing information in an electronic format that FDA can process, review, and archive. The document provides guidance on what required and FDA-recommended information related to drug establishment registration and drug listing to submit and on how to electronically prepare and submit the information to FDA.
Approaches to Reduce Risk of Transfusion-Transmitted Babesiosis in the United States; Public Workshop
Document Number: E8-15799
Type: Notice
Date: 2008-07-11
Agency: Food and Drug Administration, Department of Health and Human Services
Global Harmonization Task Force, Study Groups 1 and 5; Proposed and Final Documents; Availability
Document Number: E8-15797
Type: Notice
Date: 2008-07-11
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of final and proposed documents that have been prepared by Study Groups 1 and 5 of the Global Harmonization Task Force (GHTF), respectively. These documents represent a harmonized proposal and recommendation from the GHTF Study Groups that may be used by governments developing and updating their regulatory requirements for medical devices. These documents are intended to provide information only and do not describe FDA's current regulatory requirements; elements of these documents may not be consistent with current U.S. regulatory requirements. In particular, FDA seeks comments on the advantages and disadvantages of the approaches in the GHTF documents, particularly where they are not consistent with current practices for the manufacture of products in the United States.
Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Exceptions or Alternatives to Labeling Requirements for Products Held by the Strategic National Stockpile
Document Number: E8-15795
Type: Notice
Date: 2008-07-11
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing that a collection of information entitled ``Exceptions or Alternatives to Labeling Requirements for Products Held by the Strategic National Stockpile'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
Guidance for Industry and Food and Drug Administration Staff; Surveillance and Detention Without Physical Examination of Surgeons' and/or Patient Examination Gloves; Availability
Document Number: E8-15766
Type: Notice
Date: 2008-07-11
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of the guidance entitled ``Surveillance and Detention Without Physical Examination of Surgeons' and/or Patient Examination Gloves.'' This guidance document provides information to FDA staff and industry about FDA's strategy for addressing further imports of surgeons' and patient examination gloves (medical gloves) from manufacturers/shippers whose medical gloves have failed to meet FDA's minimum acceptable quality criteria. The guidance and the strategy are intended to help assure that medical gloves imported to the United States meet FDA's minimum acceptable quality criteria and do not have defects that could compromise their effectiveness and pose a health hazard to healthcare professionals and patients who rely on medical gloves for protection from blood- and fluid-borne pathogens.
Guidance for Industry and Food and Drug Administration Staff; Surveillance and Detention Without Physical Examination of Condoms; Availability
Document Number: E8-15765
Type: Notice
Date: 2008-07-11
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of the guidance entitled ``Surveillance and Detention Without Physical Examination of Condoms.'' This guidance document provides information to FDA staff and industry about FDA's strategy for addressing further imports of condoms from manufacturers/shippers whose condoms have failed to meet FDA's minimum acceptable quality criteria. The guidance and the strategy are intended to help assure that condoms imported to the United States do not have defects that could compromise their effectiveness and present a health hazard to consumers who rely on condoms for protection from sexually transmitted diseases as well as for contraception.
Center for Substance Abuse Treatment; Notice of Meeting
Document Number: E8-15757
Type: Notice
Date: 2008-07-11
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
Center for Substance Abuse Prevention; Notice of Meeting
Document Number: E8-15756
Type: Notice
Date: 2008-07-11
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
Tribal Self-Governance Program; Planning Cooperative Agreement
Document Number: E8-15629
Type: Notice
Date: 2008-07-11
Agency: Department of Health and Human Services, Indian Health Service
Submission for OMB Review; Comment Request
Document Number: E8-15502
Type: Notice
Date: 2008-07-11
Agency: Department of Health and Human Services, Administration for Children and Families, Children and Families Administration
Submission for OMB Review; Comment Request
Document Number: E8-15501
Type: Notice
Date: 2008-07-11
Agency: Department of Health and Human Services, Administration for Children and Families, Children and Families Administration
National Heart, Lung, and Blood Institute; Notice of Closed Meetings
Document Number: E8-15374
Type: Notice
Date: 2008-07-11
Agency: Department of Health and Human Services, National Institutes of Health
Division of Nursing, Office of Public Health Nursing
Document Number: E8-15773
Type: Notice
Date: 2008-07-10
Agency: Department of Health and Human Services, Indian Health Service
Agency Forms Undergoing Paperwork Reduction Act Review
Document Number: E8-15749
Type: Notice
Date: 2008-07-10
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Draft Guidance for Industry on Voluntary Third-Party Certification Programs for Foods and Feeds; Availability
Document Number: E8-15715
Type: Notice
Date: 2008-07-10
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ``Voluntary Third-Party Certification Programs for Foods and Feeds.'' This draft guidance describes the general attributes FDA believes a voluntary third-party certification program should have in order to help ensure its certification is a reliable reflection that the foods and feeds from certified establishments are safe and meet applicable FDA requirements.
Voluntary Third-Party Certification Programs for Imported Aquacultured Shrimp; Notice of Pilot Program
Document Number: E8-15713
Type: Notice
Date: 2008-07-10
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is seeking third-party certification bodies that certify foreign processors of aquacultured shrimp for compliance with FDA's Seafood Hazard Analysis and Critical Control Point (HACCP) regulations to volunteer to participate in a pilot program to be conducted by FDA's Center for Food Safety and Applied Nutrition (CFSAN) and Office of Regulatory Affairs (ORA). The goal of the pilot program is to gather technical and operational information that will assist FDA in determining its infrastructure needs, as well as the process for evaluating third-party certification programs, in order to assist FDA in moving towards broader recognition of voluntary third-party certification programs, including third-party certification programs for aquacultured shrimp, at a later time.
Office of Refugee Resettlement
Document Number: E8-15633
Type: Notice
Date: 2008-07-10
Agency: Department of Health and Human Services, Administration for Children and Families, Children and Families Administration
Agency Forms Undergoing Paperwork Reduction Act Review
Document Number: E8-15630
Type: Notice
Date: 2008-07-10
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Applications for Approval to Market a New Drug; Complete Response Letter; Amendments to Unapproved Applications
Document Number: E8-15608
Type: Rule
Date: 2008-07-10
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is amending its regulations on new drug applications (NDAs) and abbreviated new drug applications (ANDAs) for approval to market new drugs and generic drugs (drugs for which approval is sought in an ANDA). The final rule discontinues FDA's use of approvable letters and not approvable letters when taking action on marketing applications. Instead, we will send applicants a complete response letter to indicate that the review cycle for an application is complete and that the application is not ready for approval. We are also revising the regulations on extending the review cycle due to the submission of an amendment to an unapproved application and starting a new review cycle after the resubmission of an application following receipt of a complete response letter. In addition, we are adding to the regulations on biologics license applications (BLAs) provisions on the issuance of complete response letters to BLA applicants. We are taking these actions to implement the user fee performance goals referenced in the Prescription Drug User Fee Amendments of 2002 (PDUFA III) that address procedures and establish target timeframes for reviewing human drug applications.
Agency Information Collection Request. 30-Day Public Comment Request; 30-day Notice
Document Number: E8-15601
Type: Notice
Date: 2008-07-09
Agency: Department of Health and Human Services
Agency Information Collection Request. 30-Day Public Comment Request
Document Number: E8-15571
Type: Notice
Date: 2008-07-09
Agency: Department of Health and Human Services
Government-Owned Inventions; Availability for Licensing
Document Number: E8-15562
Type: Notice
Date: 2008-07-09
Agency: Department of Health and Human Services, National Institutes of Health
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Ruminant Feed Ban Support Project; Availability of Cooperative Agreements Under a Limited Competition; Request for Applications: RFA-FD-08-008; Catalog of Federal Domestic Assistance Number: 93.449
Document Number: E8-15561
Type: Notice
Date: 2008-07-09
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA), Office of Regulatory Affairs (ORA), Division of Federal-State Relations (DFSR) in coordination with the Center for Veterinary Medicine (CVM), is announcing the availability of cooperative agreements funding to further enhance the infrastructure of State, territorial, and tribal animal feed safety and bovine spongiform encephalopathy (BSE) prevention programs. These cooperative agreements are intended to fund additional personnel, equipment, supplies, and training support activities related to the FDA ruminant feed ban (referred to as the BSE/ruminant feed ban), in State, territory, and tribal governments. FDA anticipates providing approximately $1 million in direct plus indirect costs in support of this program in fiscal year (FY) 2008. It is anticipated that four awards will be made for up to $250,000 per award per year for up to 2 years.
National Toxicology Program (NTP); Request for Information (RFI): High Throughput Screening (HTS) Approaches for Toxicology
Document Number: E8-15560
Type: Notice
Date: 2008-07-09
Agency: Department of Health and Human Services, National Institutes of Health
This notice is for planning purposes only. It does not constitute a solicitation or Request for Proposal (RFP), nor does it restrict the Government as to the ultimate acquisition approach. The Government does not intend to award a contract on the basis of this RFI or to otherwise pay for the information solicited. Any contract that might be awarded based on information received or derived from this RFI will be the outcome of the competitive process. Any purchases that might result from information received or derived from this RFI will be at the discretion of the Government. Purpose: To ensure development of a rigorous and comprehensive battery of HTS assays, the NTP seeks information and comments on the identification and selection of critical cellular toxicity pathways for interrogation in cell-based high throughput screens. The NTP is also interested in receiving recommendations on particular molecular targets within these critical cellular toxicity pathways that are most informative for profiling the pathways, both in cell-based and biochemical assay formats. In addition to information on cellular pathways and targets, the NTP seeks information on technologies and assay systems that might be used in the development of a comprehensive approach to high throughput toxicity screening. Responses to RFI: The Government requests a brief (no more than 1 page) description of the proposed presentation addressing one or more of the points listed below or other directly related topics. In considering responses to this RFI, please keep in mind the assay protocol requirements for assays run at the NIH Chemical Genomics Center (NCGC) (http://www.ncgc.nih.gov/guidance/HTS_Assay_Guidance_ Criteria.html ). Recommendations on the identification and selection of critical cellular pathways involved in toxicity and associated with a phenotypic manifestation of toxicity in vivo (disease outcome). Information on assays that can be used to measure the activity of a compound on a target within a critical pathway. Information on the selection of the best targets within pathways and networks in order to accurately and fully characterize the activity of a compound within a specific pathway or the ability of a compound to trigger a stress-responsive pathway resulting in a defined toxicity or disease. Information on assays, technologies, or methods that will aid in identifying compounds which are active only after metabolic activation. New technologies or technologies under development that can be exploited in HTS programs, such as those underway at the NCGC or as secondary, targeted, follow-up testing to expand and more carefully characterize the findings from initial screens. All responses should include the following information: Company name, company address, name of presenter, telephone number, and e-mail address. Responses should be submitted by August 11, 2008, either electronically via the meeting Web site or by fax, e-mail, or mail to: Jennifer Smith, Contract Specialist, NIEHS, P.O. Box 12874, Mail Drop EC-02, 79 T.W. Alexander Drive, Building 4401, Room 134, Research Triangle Park, NC 27709; fax: 919-541-2712; e-mail: smithj3@niehs.nih.gov. Responses will be reviewed to ensure that the Government, by extending an invitation to a party to participate in the RFI meeting, will receive information directly relevant to its HTS program for toxicity assessment and that the party fully understands the nature of the meeting and the type of information sought. Acknowledgement of receipt of responses will not be made nor will respondents be notified of the Government's assessment of the information received. No basis for claims against the Government shall arise as a result of a response to this request for information or in the Government's use of such information as either part of its evaluation process or to develop specifications for any subsequent announcement. Responses will not be returned. The summarized responses (without identifiers) may appear in internal reports or be made public. Although the NIH will provide safeguards to prevent the release of identifying information, there is no guarantee of confidentiality. Attendance and Registration: An informational public meeting will be held on September 11-12, 2008, at the National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709. Attendance at the meeting is limited only by the available space. The purpose of this meeting is for interested parties to provide the Government information about assays, molecular targets, and cellular pathways through brief presentations and a question and answer session. Parties interested in making a presentation at the meeting must register on the meeting Web site: (http://ntp.niehs.nih.gov/go/32908). Attendees not making presentations are also encouraged to register at the Web site for planning purposes. The Government anticipates that registered presenters will be allotted 20 minutes each for presentations (limit of one speaker per organization); however, the Government retains the right to limit the number of presentations and/ or limit the allotted time for presentations based upon the number of registered presenters. Presenters will be notified about the scheduled order of presentations and the list of presenters will be posted on the meeting Web site at least one week prior to the meeting. It is anticipated that the meeting will include time for questions and information exchange. The slides from the presentations may appear in internal reports or be made public. Further information will be made available on the meeting Web site. Persons needing interpreting services in order to attend should contact 301-402-8180 (voice) or 301- 435-1908 (TTY). For other special accommodations while on NIEHS campus, contact 919-541-2475 or e-mail niehsoeeo@niehs.nih.gov.
Announcement of the Fourth Meeting of the Secretary's Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2020
Document Number: E8-15548
Type: Notice
Date: 2008-07-09
Agency: Department of Health and Human Services
The U.S. Department of Health and Human Services (HHS) announces the fourth in a series of federal advisory committee meetings regarding the national health promotion and disease prevention objectives for 2020, to be held online (via WebEx software). This meeting will be the equivalent of an in-person meeting of the Committee, and will be open to the public. The Secretary's Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2020 will review the nation's health promotion and disease prevention objectives and efforts to develop goals and objectives to improve the health status and reduce health risks for Americans by the year 2020. The Committee will provide to the Secretary of Health and Human Services advice and consultation for developing and implementing the next iteration of national health promotion and disease prevention goals and objectives and provide recommendations for initiatives to occur during the initial implementation phase of the goals and objectives. HHS will use the recommendations to inform the development of the national health promotion and disease prevention objectives for 2020 and the process for implementing the objectives. The intent is to develop and launch objectives designed to improve the health status and reduce health risks for Americans by the year 2020.
Center for Mental Health Services; Notice of Meeting
Document Number: E8-15541
Type: Notice
Date: 2008-07-09
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
Center for Scientific Review; Notice of Closed Meetings
Document Number: E8-15469
Type: Notice
Date: 2008-07-09
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Child Health and Human Development; Notice of Meeting
Document Number: E8-15467
Type: Notice
Date: 2008-07-09
Agency: Department of Health and Human Services, National Institutes of Health